Anti-hdv-igm levels as a marker of disease activity and response to pegylated interferon-α based therapy in hepatitis delta

Wranke, AnikaYurdaydin, CihanHeidrich, BenjaminErnst, StefanieKoch, ArminSerrano, Beatriz CalleCaruntu, Florin A.Curescu, Manuela G.Yalçın, KendalZeuzem, StefanErhardt, AndreasLueth, StefanPapatheodoridis, George V.Bremer, BirgitStift, JudithKirschner, JaninaPort, KerstinCornberg, MarkusDienes, Hans P.Hardtke, SvenjaManns, Michael P.Wedemeyer, Heiner2024-08-162024-08-162013-10-010270-9139https://hdl.handle.net/11452/44097Bu çalışma, 01-05 Kasım 2013 tarihleri arasında Washington[ABD]’da düzenlenen 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases’da bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/closedAccessScience & technologyLife sciences & biomedicineGastroenterology & hepatologyGastroenterology & hepatologyAnti-hdv-igm levels as a marker of disease activity and response to pegylated interferon-α based therapy in hepatitis deltaMeeting Abstract000330252203098651A651A58Supplement1, Special IssueSI